2017年严重主动脉瓣狭窄患者治疗适宜使用标准:美国心脏病学会适宜使用标准工作组及 American Association for Thoracic Surgery、American Heart Association、American Society of Echocardiography、European Association for Cardio-Thoracic Surgery、Heart Valve Society、Society of Cardiovascular Anesthesiologists、Society for Cardiovascular Angiography
美国心脏病学会联合多家学会制定首部严重主动脉瓣狭窄治疗适宜使用标准,基于2014年AHA/ACC瓣膜病指南及2017年聚焦更新,构建95个临床场景并独立评分,判定多数有症状、中高危外科风险患者行SAVR或TAVR为适宜,同时明确指征不清晰或两者均不适宜的情形。
要点
- 本适宜使用标准针对严重主动脉瓣狭窄,覆盖SAVR与TAVR两种治疗选择。
- 评分1-3分为「极少适宜」,4-6分为「可能适宜」,7-9分为「适宜」。
- 多数有症状、中等或高外科风险的严重AS患者,SAVR或TAVR均评为适宜。
核心结论
- 该适宜使用标准旨在指导临床医生依据多种临床场景识别合理的治疗与干预选择,并作为教育与质量改进工具,识别诊疗模式、减少临床实践中极少适宜的干预。
研究设计与样本
- 由美国心脏病学会与多家学会合作制定,基于2014年AHA/ACC瓣膜病管理指南及2017年聚焦更新等指南、临床试验数据与专家意见构建临床场景,由独立评分小组对每个指征按1-9分评分。
诊断标准与关键数值
- 评分1-3分归类为「极少适宜」,4-6分为「可能适宜」,7-9分为「适宜」;共识别95个基于患者症状与临床表现的临床场景,每个场景最多6种潜在治疗选择。
临床应用与阅片要点
- 评分小组在考虑症状状态、左心室功能、外科风险及合并冠状动脉或其他瓣膜病等因素后判定,多数有症状、中等或高外科风险的AS患者行SAVR或TAVR为适宜;临床实践中常见SAVR或TAVR指征不明确的情形,包括一种瓣膜置换看似合理而另一种不太合理,以及两者均非合适治疗选择的情况。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The American College of Cardiology collaborated with the American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Valve Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons to develop and evaluate Appropriate Use Criteria (AUC) for the treatment of patients with severe aortic stenosis (AS). This is the first AUC to address the topic of AS and its treatment options, including surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). A number of common patient scenarios experienced in daily practice were developed along with assumptions and definitions for those scenarios, which were all created using guidelines, clinical trial data, and expert opinion in the field of AS. The 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(1) and its 2017 focused update paper (2) were used as the primary guiding references in developing these indications. The writing group identified 95 clinical scenarios based on patient symptoms and clinical presentation, and up to 6 potential treatment options for those patients. A separate, independent rating panel was asked to score each indication from 1 to 9, with 1-3 categorized as "Rarely Appropriate," 4-6 as "May Be Appropriate," and 7-9 as "Appropriate." After considering factors such as symptom status, left ventricular (LV) function, surgical risk, and the presence of concomitant coronary or other valve disease, the rating panel determined that either SAVR or TAVR is Appropriate in most patients with symptomatic AS at intermediate or high surgical risk; however, situations commonly arise in clinical practice in which the indications for SAVR or TAVR are less clear, including situations in which 1 form of valve replacement would appear reasonable when the other is less so, as do other circumstances in which neither intervention is the suitable treatment option. The purpose of this AUC is to provide guidance to clinicians in the care of patients with severe AS by identifying the reasonable treatment and intervention options available based on the myriad clinical scenarios with which patients present. This AUC document also serves as an educational and quality improvement tool to identify patterns of care and reduce the number of rarely appropriate interventions in clinical practice.
引用
- Bonow RO, Brown AS, Gillam LD, et al. ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for the Treatment of Patients With Severe Aortic Stenosis: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Valve Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Soc Echocardiogr. 2017. PMID: 29254695. doi:10.1016/j.echo.2017.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。